title: Influence of a randomized monoclonal or polyclonal program of therapy on cytomegalovirus infection in kidney transplantation.
authors.affiliation: Transplantation Unit, E. Herriot Hospital, Lyon, France.
authors.forename: P
authors.initials: P
authors.lastname: Raffaele
authors.forename: C
authors.initials: C
authors.lastname: Pouteil-Noble
authors.forename: N
authors.initials: N
authors.lastname: Lefrancois
authors.forename: S
authors.initials: S
authors.lastname: Bosshard
authors.forename: H
authors.initials: H
authors.lastname: Betuel
authors.forename: M
authors.initials: M
authors.lastname: Aymard
authors.forename: J M
authors.initials: JM
authors.lastname: Dubernard
authors.forename: J L
authors.initials: JL
authors.lastname: Touraine
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000961:Antilymphocyte Serum / Q000008:administration & dosage*; D003586:Cytomegalovirus Infections / Q000150:complications*; D006084:Graft Rejection; D006680:HLA Antigens / Q000276:immunology; D006648:Histocompatibility; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D016030:Kidney Transplantation / Q000379:methods*; D016853:Muromonab-CD3
chemical_list: D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D006680:HLA Antigens; D016853:Muromonab-CD3